Elutia Stock (NASDAQ:ELUT)

Elutia Inc. is a commercial-phase biotechnology firm specializing in the creation and market introduction of advanced biologic products designed to deliver therapeutic agents. These innovative solutions cater to diverse medical fields such as neurostimulation, advanced wound management, and reconstructive breast surgery within the United States. Its operations are structured across three primary divisions: Device Protection, Women's Health, and Cardiovascular. The company's product portfolio includes several key offerings: CanGaroo Envelope: An innovative mesh envelope engineered to securely house cardiac implantable electronic devices (CIEDs), such as pacemakers and internal defibrillators. CanGarooRM: A variant of the CanGaroo Envelope, this version is infused with antibiotics, specifically formulated to mitigate post-surgical infection risks associated with electronic device implantation. ProxiCor: Utilized for essential cardiac tissue repair and pericardial closure procedures. Tyke: An extracellular matrix material developed for the critical repair of cardiac structures in neonate and infant patients. VasCure: A patch material employed for the reconstruction or repair of peripheral vasculature. SimpliDerm: Comprises human acellular dermal matrices, widely utilized for tissue regeneration and reconstruction in diverse surgical applications, including sports medicine, hernia repair, trauma reconstruction, and post-mastectomy breast reconstruction procedures. Elutia distributes its product range to hospitals and healthcare providers throughout the U.S. through a multi-channel approach, leveraging its direct sales team, independent sales agents, and a network of distributors. The company, formerly known as Aziyo Biologics, Inc., rebranded as Elutia Inc. in September 2023. Founded in 2015, Elutia maintains its corporate headquarters in Silver Spring, Maryland.